Merkel cell carcinoma: evaluation of KIT (CD117) expression and failure to demonstrate activating mutations in the C-KIT proto-oncogene - implications for treatment with imatinib mesylate.

@article{Swick2007MerkelCC,
  title={Merkel cell carcinoma: evaluation of KIT (CD117) expression and failure to demonstrate activating mutations in the C-KIT proto-oncogene - implications for treatment with imatinib mesylate.},
  author={Brian L. Swick and Larisa Ravdel and James E. Fitzpatrick and William A. Robinson},
  journal={Journal of cutaneous pathology},
  year={2007},
  volume={34 4},
  pages={
          324-9
        }
}
BACKGROUND Merkel cell carcinomas (MCCs) express the tyrosine kinase receptor KIT. However, it is not known if MCCs have activating mutations in KIT that would make them responsive to treatment with imatinib mesylate. The purpose of this article is to describe the KIT immunohistological staining pattern (CD117) of MCCs and analyze those MCCs for mutations in areas of KIT where mutations are found in gastrointestinal stromal cell tumors. METHODS We evaluated KIT immunostaining in nine MCCs… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 31 CITATIONS

Post-transplant Merkel Cell Carcinoma.

  • Acta dermato-venereologica
  • 2016
VIEW 1 EXCERPT
CITES BACKGROUND

Merkel cell carcinoma - recent advances in the biology, diagnostics and treatment.

  • The international journal of biochemistry & cell biology
  • 2014
VIEW 1 EXCERPT
CITES BACKGROUND

Merkel cell carcinoma.

  • Hematology/oncology clinics of North America
  • 2012
VIEW 1 EXCERPT
CITES RESULTS